Advanced search
Publication Cover
International Journal of Healthcare Management Volume 15, 2022 - Issue 1
Submit an article Journal homepage
55
Views
1
CrossRef citations to date
0
Altmetric
Articles

Physician’s interest to meet the sales rep and sample need: Implication to pharmaceutical detailing and sampling efforts

Eddie Rheea Leo J. Meehan School of Business, Stonehill College, Easton, MA, USACorrespondence[email protected]
View further author information
&
John C. Yib Erivan K. Haub School of Business, Saint Joseph’s UniversityView further author information
Pages 84-92 | Received 12 Feb 2020, Accepted 29 Oct 2020, Published online: 21 Dec 2020

References

  • Bala R, Bhardwaj P. Detailing vs. direct-to-consumer advertising in the prescription pharmaceutical industry. Manage Sci. 2010;56(1):148–160.
  • Bala R, Bhardwaj P, Chen Y. Offering pharmaceutical samples: the role of physician learning and patient payment ability. Marketing Sci. 2013;32(3):522–527.
  • Chan T, Narasimhan C, Xie Y. Treatment effectiveness and side effects: a model of physician learning. Manage Sci. 2013;59(6):1309–1325.
  • Ching A, Ishihara M. The effects of detailing on prescribing decisions under quality uncertainty. Quant Marketing Econ. 2010;8(2):123–165.
  • Datta A, Dave D. Effects of physician-directed pharmaceutical promotion on prescription behaviors: longitudinal evidence. Health Econ. 2017;26(4):450–468.
  • Fischer M, Albers S. Patient- or physician-oriented marketing: what drives primary demand for prescription drugs? J Marketing Res. 2010;47(1):103–121.
  • Fong C-H, Goh Y-N. Why brand equity is so important for private healthcare? View from an emerging market. Int J Healthc Manag. 2020. DOI:https://doi.org/10.1080/20479700.2020.1755811.
  • Gonul F, Carter F, Petrova E, et al. Promotion of prescription drugs and its impact on physicians’ choice behavior. J Mark. 2001;65(3):79–90.
  • Huang G, Shum M, Tan W. Is pharmaceutical detailing informative? evidence from contraindicated drug prescriptions. Quant Marketing Econ. 2019;17(2):135–160.
  • Jamieson S. Likert scales: how to (ab)use them. Med Educ. 2004;38(12):1217–1218.
  • Janakiraman R, Dutta S, Sismeiro C, et al. Physicians’ persistence and Its implications for their response to Promotion of prescription drugs. Manage Sci. 2008;54(6):1080–1093.
  • Joseph K, Mantrala M. A model of the role of free drug samples in physicians’ prescription decisions. Mark Lett. 2009;20(1):15–29.
  • Kappe E, Stremersch S. Drug detailing and doctors’ prescription decisions: the role of information content in the face of competitive entry. Marketing Science. 2016;35(6):915–933.
  • Larkin I, Ang D, Steinhart J, et al. Association between academic medical center pharmaceutical detailing policies and physician prescribing. JAMA. 2017;317(17):1785–1795.
  • Likert R. A technique for the measurement of attitudes. Arch Psychol. 1932;140:1–55.
  • Liu H, Liu Q, Chintagunta P. Promotion spillovers: drug detailing in combination therapy. Marketing Sci. 2017;36(3):382–401.
  • Liu Q, Gupta S, Venkataraman S, et al. An empirical model of drug detailing: dynamic competition and Policy implications. Manage Sci. 2016;62(8):2321–2340.
  • Manchanda P, Chintagunta P. Responsiveness of physician prescription behavior to salesforce effort: an individual level analysis. Mark Lett. 2004;15(2-3):129–145.
  • Mizik N, Jacobson R. Are physicians “easy marks”? Quantifying the effects of detailing and sampling on new prescriptions. Manage Sci. 2004;50(12):1704–1715.
  • Montoya R, Netzer O, Jedidi K. Dynamic allocation of pharmaceutical detailing and sampling for long-term profitability. Marketing Sci. 2010;29(5):909–924.
  • Paulhus DL. Two-component models of socially desirable responding. J Pers Soc Psychol. 1984;46(3):598–609.
  • Prosser H, Almond S, Walley T. Influences on GP’s decision to prescribe New drugs – the importance of who says what. Fam Pract. 2003;20(1):61–68.
  • Shapiro B. Informational shocks, off-label prescribing, and the effects of physician detailing. Manage Sci. 2018;64:5925–5945.
  • Sillup GP, Dehshal MH, Namini MT. Pharmaceutical companies and physicians: assessing their relationship. Int J Healthc Manag. 2013;6(4):276–280.
  • Srivastava RK, Bodkhe J. Does brand equity play a role on doctors prescribing behavior in emerging markets? Int J Healthc Manag. 2018. DOI:https://doi.org/10.1080/20479700.2017.1409954.
  • Srivastava RK, Bodkhe J. Does the country of origin has impact on prescribing behavior of general practitioners? Int J Healthc Manag. 2019. DOI:https://doi.org/10.1080/20479700.2019.1684667.
  • Venkataraman S, Stremersch S. The debate on influencing doctors’ decisions: are drug characteristics the missing link? Manage Sci. 2007;53(11):1688–1701.
  • Yi J, Kim S. Early adoption of innovative analytical approach and its impact on organizational analytics maturity and sustainability: a longitudinal study from a U.S. pharmaceutical company. Sustainability. 2016;8:808.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.